Actinic Keratosis (AK) Epidemiology Forecast 2026-2035

Actinic keratosis (AK) is a common precancerous skin lesion associated with chronic ultraviolet radiation exposure. A global meta-analysis of 60 observational studies published in the British Journal of Dermatology reported an actinic keratosis prevalence of approximately 14% and an actinic keratosis incidence of about 1.9 cases per 100,000 person-years. According to the analyst, the disease burden is expected to remain significant due to aging populations and cumulative sun exposure.

Actinic Keratosis (AK) Epidemiology Forecast Report Coverage

The analyst's “Actinic Keratosis (AK) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of actinic keratosis (AK). It projects the future incidence and prevalence rates of actinic keratosis (AK) cases across various populations. The study covers age, gender, and type as major determinants of the actinic keratosis (AK) population. The report highlights patterns in the prevalence of actinic keratosis (AK) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of actinic keratosis (AK) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Actinic Keratosis (AK) Understanding: Disease Overview

Actinic Keratosis is a common precancerous skin condition caused by prolonged uv exposure, leading to cumulative sun damage. It typically presents a rough skin lesion or abnormal skin growth, often appearing as rough patches or scaly skin on sun-exposed areas such as the face, scalp, and hands. These lesions arise due to keratinocyte damage and can progress to skin cancer, particularly squamous cell carcinoma, if untreated. Clinically, actinic keratosis may be classified into hypertrophic, atrophic, or pigmented forms based on lesion characteristics.

Actinic Keratosis (AK) Epidemiology Perspective

The actinic keratosis (AK) epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the actinic keratosis (AK) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for actinic keratosis (AK) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Maria Antonia De Francesco et al., (2025), the global prevalence of actinic keratosis is about 14%, affecting nearly 1.1 billion individuals worldwide, highlighting its significant global disease burden, particularly in populations exposed to prolonged ultraviolet radiation.
• As per Hafid Belhadj-Tahar et al., (2025), age-specific prevalence increases with age and cumulative sun exposure, affecting 15-25% of individuals older than 60 years in Europe and exceeding 60% in highly sun-exposed regions such as Australia.
• Actinic keratosis, according to Justyna Ceryn et al., (2025), primarily affects the elderly population, with age-related incidence trends reported at 4.6% among individuals aged 60-69 years and 14.57% among those older than 80 years, reflecting a strong epidemiological pattern.
• As per Maria Antonia De Francesco et al., (2025), gender-based incidence shows a higher occurrence in men (3.5%) compared to women (1.5%), largely attributed to occupational sun exposure and male-pattern balding.
• According to MD Anderson Cancer Center, actinic keratosis is a precancerous lesion with 1-10% of cases progressing to squamous cell carcinoma, while other studies report an annual progression risk ranging from 0.025% to 16%, emphasizing its clinical and epidemiological significance.

Country-wise Actinic keratosis (AK) Epidemiology

The actinic keratosis (AK) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of actinic keratosis (AK) varies across major global regions, largely driven by ultraviolet radiation exposure, aging populations, and skin phototype distribution, contributing to rising UV-induced skin lesions and a growing dermatologic disease burden globally. According to Erik Marques et al., 2024, the prevalence in the United States is approximately 20%, reflecting a substantial burden in non-equatorial regions. As per DynaMedex, the United Kingdom reports prevalence rates of 15.4% in males and 5.9% in females, while Italy shows a prevalence of 27.4%. According to J. Cañueto et al., 2025, AK accounts for nearly 6% of dermatology consultations in Spain, with prevalence reaching 28.6% among patients aged 45 years or older, indicating significant regional variation.

Actinic keratosis (AK): Treatment Overview

Management of Actinic Keratosis focuses on preventing progression to skin cancer through effective dermatology treatment approaches. Common interventions include cryotherapy treatment, which uses liquid nitrogen to destroy abnormal cells, and photodynamic therapy, which involves light-activated agents to target lesions. Topical therapy options, such as imiquimod cream, stimulate immune responses to eliminate atypical cells. Additional treatments may include 5-fluorouracil or diclofenac gels. Early diagnosis and tailored treatment strategies are essential for lesion clearance and reducing recurrence risk.

Key Questions Answered

• What are the key findings of actinic keratosis (AK) epidemiology in the 8 major markets?
• What will be the total number of patients with actinic keratosis (AK) across the 8 major markets during the forecast period?
• What was the country-wise actinic keratosis (AK) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of actinic keratosis (AK) patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of actinic keratosis (AK) during the forecast period of 2026-2035?
• What are the currently available treatments for actinic keratosis (AK)?
• What are the disease risks, signs, symptoms, and unmet needs of actinic keratosis (AK)?

Scope of the Actinic Keratosis (AK) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of actinic keratosis (AK) based on several factors.
• Actinic Keratosis (AK) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The actinic keratosis (AK) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.